» Articles » PMID: 15305849

Modeling and Allometric Scaling of S(+)-ketoprofen Pharmacokinetics and Pharmacodynamics: a Retrospective Analysis

Overview
Specialty Pharmacology
Date 2004 Aug 13
PMID 15305849
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Interspecies scaling of pharmacokinetic (PK) parameters is commonplace in drug development. However, information about proportionality of pharmacodynamic (PD) parameters in different species is scarce. We investigated the feasibility of allometric scaling of PK and PD parameters of s(+)-ketoprofen (sKTP) using the literature data from several animal species. Two different indirect response models were proposed to characterize sKTP inhibitory effects on synthesis of thromboxane B(2) (TXB(2)) and prostaglandin E(2) (PGE(2)). Using the traditional allometric approach, the obtained PK and PD parameters were plotted against body weights (BW) on a log-log scale. For all species, values of systemic clearance (Cl), distribution clearance (Cl(D)), central volume of distribution (V(c)), and volume of distribution at steady-state (V(ss)) were highly correlated (r(2) = 0.89-0.99) with BW. The PD parameters for inhibition of TXB(2) synthesis were poorly correlated with BW (r(2) = 0.25-0.54) while most of the parameters for inhibition of PGE(2) synthesis lacked any correlation (r(2) approximately 0.05). In conclusion, indirect response models adequately described the time course of sKTP inhibitory effects on synthesis of TXB(2) and PGE(2). Allometrical scaling showed PK parameters to change proportionally to BW, whereas PD parameters had limited ranges and were essentially weight independent.

Citing Articles

Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches.

Song D, Jusko W Biopharm Drug Dispos. 2021; 42(5):191-203.

PMID: 33638217 PMC: 8859844. DOI: 10.1002/bdd.2266.


Modeling of prolactin response following dopamine D receptor antagonists in rats: can it be translated to clinical dosing?.

Taneja A, Vermeulen A, Huntjens D, Danhof M, de Lange E, Proost J Pharmacol Res Perspect. 2017; 5(6).

PMID: 29226628 PMC: 5723698. DOI: 10.1002/prp2.364.


Model-Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion.

Cirincione B, LaCreta F, Sager P, Mager D J Clin Pharmacol. 2017; 57(8):956-965.

PMID: 28543393 PMC: 5518197. DOI: 10.1002/jcph.882.


Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model.

Petersson K, Vermeulen A, Friberg L AAPS J. 2013; 15(2):533-41.

PMID: 23392818 PMC: 3675734. DOI: 10.1208/s12248-012-9450-6.


Pharmacokinetic/pharmacodynamic modeling in inflammation.

Lon H, Liu D, Jusko W Crit Rev Biomed Eng. 2012; 40(4):295-312.

PMID: 23140121 PMC: 3538354. DOI: 10.1615/critrevbiomedeng.v40.i4.50.